Dashboard
Manage Tickers

GLUE Monte Rosa Therapeutics, Inc.

Nasdaq monterosatx.com


$ 13.80 $ 0.17 (1.25 %)    

Tuesday, 18-Nov-2025 15:57:59 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ $ 597.12 $ -7.35 (-1.22 %)
DIA $ 461.67 $ -5.02 (-1.08 %)
SPY $ 660.81 $ -5.59 (-0.84 %)
TLT $ 89.05 $ -0.03 (-0.03 %)
GLD $ 374.31 $ 2.70 (0.73 %)
$ 13.78
$ 13.45
$ 13.68 x 200
$ 13.69 x 3
$ 13.01 - $ 13.81
$ 3.50 - $ 14.62
743,251
na
897.32M
$ 1.97
$ 44.82
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-06-2025 09-30-2025 10-Q
2 08-07-2025 06-30-2025 10-Q
3 05-08-2025 03-31-2025 10-Q
4 03-20-2025 12-31-2024 10-K
5 11-07-2024 09-30-2024 10-Q
6 08-08-2024 06-30-2024 10-Q
7 05-09-2024 03-31-2024 10-Q
8 03-14-2024 12-31-2023 10-K
9 11-09-2023 09-30-2023 10-Q
10 08-10-2023 06-30-2023 10-Q
11 05-11-2023 03-31-2023 10-Q
12 03-16-2023 12-31-2022 10-K
13 11-10-2022 09-30-2022 10-Q
14 08-11-2022 06-30-2022 10-Q
15 05-11-2022 03-31-2022 10-Q
16 03-29-2022 12-31-2021 10-K
17 11-10-2021 09-30-2021 10-Q
18 08-12-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

reported-saturday-monte-rosa-therapeutics-presents-preclinical-data-at-aha-2025-demonstrating-mrt-8102-nek7-directed-molecular-glue-degrader-modulates-nlrp3-inflammasome-in-cardiovascular-and-cardiometabolic-diseases
Reported Saturday, Monte Rosa Therapeutics...
11/10/2025 09:03:36

Data support NEK7 as a potential novel and differentiated therapeutic approach to modulate the NLRP3 inflammasome in multiple c...

wells-fargo-maintains-equal-weight-on-monte-rosa-therapeutics-raises-price-target-to-13
Wells Fargo Maintains Equal-Weight on Mont...
11/07/2025 18:43:54

Wells Fargo analyst Derek Archila maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Equal-Weight and raises the price t...

monte-rosa-therapeutics-q3-eps-033-beats-037-estimate-sales-12768m-beat-5420m-estimate
Monte Rosa Therapeutics Q3 EPS $(0.33) Bea...
11/06/2025 13:01:01

Monte Rosa Therapeutics (NASDAQ:GLUE) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate ...

monte-rosa-therapeutics-q3-sales-12768m-beat-5420m-estimate
Monte Rosa Therapeutics Q3 Sales $12.768M ...
11/06/2025 12:24:07

Monte Rosa Therapeutics (NASDAQ:GLUE) reported quarterly sales of $12.768 million which beat the analyst consensus estimate of ...

monte-rosa-therapeutics-unveils-preclinical-data-showing-mrt-6160-reduces-autoimmune-disease-markers-supports-potential-in-sle-sjgrens-and-ra-phase-2-planned-with-novartis
Monte Rosa Therapeutics Unveils Preclinica...
10/24/2025 11:04:16

dave--busters-entertainment-posts-downbeat-results-joins-adtran-holdings-and-other-big-stocks-moving-lower-in-tuesdays-pre-market-session
Dave & Buster's Entertainment Posts Downbe...
09/16/2025 13:02:27

why-webtoon-entertainment-shares-are-trading-higher-by-48-here-are-20-stocks-moving-premarket
Why Webtoon Entertainment Shares Are Tradi...
09/16/2025 09:41:12

Core News & Articles
12 Health Care Stocks Moving In Monday's I...
09/15/2025 17:06:06

monte-rosa-novartis-use-ai-powered-engine-to-advance-immune-disease-treatments
Monte Rosa, Novartis Use AI-Powered Engine...
09/15/2025 15:29:40

Monte Rosa's stock jumps as it partners with Novartis to develop degraders for immune diseases, with up to $5.7 billion in ...

Core News & Articles
12 Health Care Stocks Moving In Monday's P...
09/15/2025 12:10:36

Core News & Articles
Market-Moving News for Sept 15
09/15/2025 11:25:55

CHEK: 301% | MBody AI and Check-Cap Enter into Definitive Merger Agreement EVTV: 125% | Envirotech Unveils US-Made Heavy-Lift D...

monte-rosa-therapeutics-to-collaborate-with-novartis-to-develop-novel-degraders-for-immune-mediated-diseases
Monte Rosa Therapeutics To Collaborate Wit...
09/15/2025 11:04:23

Novartis receives an exclusive license to an undisclosed discovery targetNovartis also receives options to license two programs...

monte-rosa-therapeutics-q2-eps-015-beats-039-estimate-sales-2319m-beat-1080m-estimate
Monte Rosa Therapeutics Q2 EPS $(0.15) Bea...
08/07/2025 11:21:07

Monte Rosa Therapeutics (NASDAQ:GLUE) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate ...

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
07/22/2025 21:06:00

monte-rosa-announces-first-subjects-dosed-in-phase-1-study-evaluating-mrt-8102-nek7-directed-mgd-being-developed-for-treatment-of-inflammatory-conditions-driven-by-nlrp3-inflammasome-il-1-and-il-6-initial-results-from-phase-1-study-expected-in-h1-2026
Monte Rosa Announces First Subjects Dosed ...
07/21/2025 11:07:19

MRT-8102 Phase 1 study includes single and multiple ascending dose cohorts in healthy volunteers and is designed to evaluate sa...

monte-rosa-therapeutics--announces-the-publication-of-groundbreaking-new-discoveries-featured-on-the-cover-of-science-titled-mining-the-crbn-target-space-redefines-rules-for-molecular-glue-induced-neosubstrate-recognition
Monte Rosa Therapeutics Announces The Pub...
07/03/2025 18:16:52

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (M...

monte-rosa-therapeutics-advances-nek7-program-with-enhanced-cns-penetration-ind-filing-slated-for-2026
Monte Rosa Therapeutics Advances NEK7 Prog...
06/10/2025 11:07:09

In addition to MRT-8102, Monte Rosa is also working to advance a second-generation NEK7 program with enhanced CNS penetration w...

monte-rosa-therapeutics-plans-to-initiate-phase-1-study-of-mrt-8102-in-coming-weeks-and-anticipates-sharing-initial-results-in-h1-2026
Monte Rosa Therapeutics Plans To Initiate ...
06/10/2025 11:05:10

fda-clears-ind-application-for-monte-rosa-therapeutics-mrt-8102-nek7-directed-mgd-developed-to-treat-inflammatory-conditions-linked-to-nlrp3-il-1-and-il-6-dysregulation
FDA Clears IND Application For Monte Rosa ...
06/10/2025 11:04:34

MRT-8102, a highly selective NEK7-directed molecular glue degrader (MGD) developed to treat inflammatory conditions linked to N...

monte-rosa-therapeutics-q1-eps-057-beats-030-estimate-sales-8493m-beat-1425m-estimate
Monte Rosa Therapeutics Q1 EPS $0.57 Beats...
05/08/2025 11:24:02

Monte Rosa Therapeutics (NASDAQ:GLUE) reported quarterly earnings of $0.57 per share which beat the analyst consensus estimate ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION